GE HealthCare
GE HealthCare is a globally recognized leader in medical technologies and digital solutions, dedicated to improving patient outcomes and transforming healthcare delivery worldwide. The company became an independent publicly traded entity in January 2023 following its separation from General Electric. Its nuclear medicine portfolio is a cornerstone of its Imaging segment, where it provides cutting-edge molecular imaging systems, including advanced PET/CT and SPECT/CT scanners. GE HealthCare significantly contributes to the market through proprietary software platforms like Xeleris and AI-powered tools that enhance image reconstruction and workflow optimization. A major strategic move was the acquisition of MIM Software in 2024, which expanded its capabilities in molecular imaging, image analysis, and radiation oncology. The company is committed to integrating AI-driven technologies to enable more accurate diagnostics and streamlined clinical operations across cardiology, oncology, and neurology, serving hospitals and diagnostic centers in over 160 countries.
Latest Market Research Report on Nuclear Medicine Equipment Download PDF Brochure Now
Siemens Healthineers
Siemens Healthineers is a prominent global medical technology and healthcare solutions company, a publicly held entity established in 1847. Its nuclear medicine offerings are categorized under the Molecular Imaging subsegment of its Imaging division. The company is renowned for its sophisticated hybrid imaging technologies, providing high-end PET/CT and SPECT/CT systems, which are vital for diagnostic imaging and treatment planning across complex disease areas like oncology and neurology. Flagship products such as the Biograph PET/CT and Biograph mMR PET/MR hybrid systems are complemented by advanced software platforms, including MI Applications and Syngo Via, which facilitate workflow optimization, image quantification, and multimodality integration. By emphasizing digital health innovations and AI-enabled diagnostics, Siemens Healthineers continually strives to improve diagnostic accuracy, enhance patient safety, and streamline clinical operations in nuclear medicine practices globally.
Cardinal Health
Cardinal Health is a global leader in healthcare services and products, founded in 1971 and headquartered in Dublin, Ohio. Its primary role in the nuclear medicine market is focused on being a critical link in the supply chain for radiopharmaceuticals. The company operates one of the largest networks of nuclear pharmacies in the United States, providing a comprehensive range of radiopharmaceutical distribution and nuclear pharmacy services. This ensures the reliable, timely, and compliant supply of time-sensitive diagnostic and therapeutic agents to hospitals, clinics, and research institutions. Cardinal Health has actively expanded its theranostic solutions and invested in advanced supply chain logistics and patient support programs. Its extensive infrastructure and commitment to accessibility make it an indispensable partner in the global nuclear medicine ecosystem, strengthening healthcare delivery through operational excellence.
Koninklijke Philips N.V.
Koninklijke Philips N.V., commonly known as Philips, is a global technology company recognized for its leadership in the nuclear medicine equipment market, mainly through its Connected Care and Imaging segments. Philips provides integrated molecular imaging systems, including advanced PET/CT scanners and SPECT/CT systems, that are essential for high-quality diagnostic imaging. The company leverages its expertise in molecular imaging and healthcare informatics to offer systems designed to enhance diagnostic efficiency and image quality. Key innovations, such as the Gemini PET/CT scanner with Truflight technology, focus on providing superior spatial and contrast resolution, leading to faster and more sensitive scans. Philips’ commitment is to transform healthcare delivery by providing integrated solutions that not only include the imaging equipment but also the clinical decision support software, thereby improving patient outcomes and streamlining nuclear medicine workflows.
Curium Pharma
Curium Pharma is a global leader in nuclear medicine, specializing in the development, manufacturing, and commercialization of radiopharmaceuticals for both diagnostic and therapeutic applications. With a robust portfolio used in oncology, cardiology, and neurology, Curium’s mission is to ensure healthcare professionals have reliable access to critical nuclear medicine products. The company maintains a strong global manufacturing footprint and a highly efficient supply chain, which is essential for the delivery of radioisotopes with short half-lives. Curium is a significant driver in the theranostics paradigm, actively working to develop and supply diagnostic and therapeutic radiopharmaceuticals that, when used together, offer more personalized and effective treatment options for cancer and other serious diseases. Its dedication to innovation and supply chain security solidifies its status as a major international player.
NorthStar Medical Radioisotopes
NorthStar Medical Radioisotopes is a specialized provider of therapeutic and diagnostic radioisotopes, dedicated to ensuring a reliable supply chain for nuclear medicine. The company is primarily focused on the development and production of key radioisotopes, such as Molybdenum-99 (Mo-99), the parent isotope of Technetium-99m (Tc-99m), and Actinium-225 (Ac-225). NorthStar is uniquely positioned as a domestic supplier utilizing non-reactor-based production methods, which helps to mitigate global supply dependencies and ensures a stable, high-quality source of critical medical isotopes. Their work in Actinium-225 is particularly vital for the rapidly emerging field of theranostics, supporting advanced cancer treatments. By offering contract development and manufacturing services alongside their proprietary production technologies, NorthStar plays a key role in advancing radiopharmaceutical supply chain management and enabling the growth of nuclear medicine worldwide.
Jubilant Radiopharma
Jubilant Radiopharma, a division of Jubilant Pharma Ltd., is a global leader in radiopharmaceuticals, specializing in the development, manufacturing, and commercialization of both diagnostic and therapeutic agents. Headquartered in Yardley, Pennsylvania, the company supports the nuclear medicine community with an extensive network of radiopharmacies and a comprehensive portfolio of nuclear medicine solutions. Its operational strength lies in its ability to manage the complex logistics of these time-sensitive products, ensuring timely and reliable delivery to healthcare facilities. Through its commitment to innovative radiopharmaceutical formulations and being the parent company of operations like Triad Isotopes, Jubilant Radiopharma provides essential support for clinical trials and commercial supply globally. The company is focused on enabling healthcare providers to deliver accurate diagnostics and effective, targeted treatments, thereby enhancing patient care and driving accessibility in the nuclear medicine market.
Bayer AG
Bayer AG is a German multinational pharmaceutical and life sciences company with a significant and growing presence in the radiopharmaceuticals market, primarily through its Radiology Division, with a strong focus on oncology. The company is actively involved in the development and commercialization of targeted therapeutic radiopharmaceuticals, most notably its approved alpha-emitting radiopharmaceutical for metastatic castration-resistant prostate cancer. Bayer’s strategic commitment is to translate its deep pharmaceutical expertise into the nuclear medicine space, aiming to create innovative cancer treatments that utilize targeted delivery. By focusing on radiopharmaceuticals, Bayer seeks to redefine cancer care by bridging the gap between precise molecular diagnostics and effective, high-precision therapies, thereby improving treatment options for patients globally and establishing itself as a key innovator in the theranostics field.
Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a U.S.-based pharmaceutical company specializing in precision diagnostics and targeted therapeutics, with a core focus on radiopharmaceutical oncology. The company provides a portfolio of innovative diagnostic agents used in cardiac imaging and oncology, alongside targeted therapeutic radiopharmaceuticals. Lantheus is a major market player due to its ability to integrate advanced solutions, including artificial intelligence (AI) tools, into its offerings. Through key subsidiaries, such as Lantheus Medical Imaging and Progenics Pharmaceuticals, the company is engaged in developing next-generation radiopharmaceuticals. Its strong emphasis on the theranostic model—where diagnostic and therapeutic agents are used synergistically—positions Lantheus at the forefront of personalized medicine in nuclear oncology and other complex disease areas, ensuring high-quality diagnostic imaging and effective patient treatment.
Bracco Imaging S.p.A.
Bracco Imaging S.p.A. is a global leader in diagnostic imaging, headquartered in Italy, with a significant presence in the nuclear medicine and molecular imaging markets. The company specializes in the development, manufacturing, and commercialization of contrast media and medical devices, including diagnostic radiopharmaceuticals and imaging agents. Bracco’s commitment is to enhance the quality of diagnostic information and improve the efficiency of clinical workflows across various medical fields, such as cardiology and oncology. By continuously investing in research and development, Bracco ensures its products are compatible with advanced imaging modalities like SPECT and PET. Its contribution to the nuclear medicine market centers on providing the necessary high-quality imaging agents that enable healthcare professionals to make accurate and timely diagnoses, thereby supporting critical patient care decisions worldwide.
Latest Market Research Report on Nuclear Medicine Equipment Download PDF Brochure Now